Eli Lilly’s Omvoh achieves 91% Crohn’s steroid-free remission at three years
Eli Lilly’s Omvoh (mirikizumab) has demonstrated its capacity to keep patients free from corticosteroids and promote long-term clinical remission in…
News
FDA to allow one pivotal trial instead of two for drug approval
MSD reports Phase III SMART trial outcomes for infants’ RSV risk
Serina Therapeutics enrols first patient for SER-252 trial
NeuroSense’s ALS drug improves survival in Phase IIb trial
Lilly reports positive top line data for TOGETHER-PsO Phase IIIb trial
Novartis’ RemIND trial of oral remibrutinib meets primary endpoint
Compass stock heads north on psychedelic’s Phase III TRD success
